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ABSTRACT: 
Objective: Germline loss-of-function mutations in the SPRED1 gene have recently 
been identified in patients fulfilling the National Institutes of Health (NIH) diagnostic 
criteria for neurofibromatosis type 1 (NF1) but with no NF1 (neurofibromin 1) mutation 
found, suggesting a neurofibromatosis type 1-like syndrome. 
Methods: 61 index cases with NF1 clinical diagnosis but no identifiable NF1 mutation 
were screened for SPRED1 mutation. 
Results: We described one known SPRED1 mutation (c.190C>T leading to 
p.Arg64Stop) and four novel mutations (c.637C>T leading to p.Gln213Stop, c.2T>C 
leading to p.Met1Thr, c.46C>T leading to p.Arg16Stop, and c.1048_1060del leading 
to p.Gly350fs) in five French families. Their NF1-like phenotype was characterized by 
a high prevalence of café-au-lait spots, freckling, learning disability, and an absence 
of neurofibromas and Lisch nodules in agreement with the original description. 
However, we did not observe Noonan-like dysmorphy. It is noteworthy that one 
patient with the p.Arg16Stop mutation developed a monoblastic acute leukaemia. 
Conclusions: In our series, SPRED1 mutations occurred with a prevalence of 0.5% 
in NF1 patients and in 5% of NF1 patients displaying a NF1-like phenotype. SPRED1 
mutated patients did not display any specific dermatologic features that were not 
present in NF1 patients, except for the absence of neurofibromas that seem to be a 
specific clinical feature of NF1. The exact phenotypic spectrum and the putative 
complications of this NF1 overlapping syndrome, in particular haematological 
malignancies, remain to be further characterized. NIH diagnostic criteria for NF1 must 
be revised in view of this newly characterized Legius syndrome in order to establish a 
specific genetic counselling. 
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INTRODUCTION 
Germline mutations in genes involved in the Ras-mitogen activated protein kinase 
(MAPK) signalling pathway have been reported in several phenotypically overlapping 
syndromes with autosomal dominant transmission.[1] These observations provided a 
unifying mechanism -- Ras MAPK pathway constitutive activation -- leading to neuro-
cardio-facial-cutaneous (NCFC) syndromes (Figure 1). These rare diseases include 
neurofibromatosis 1 (NF1, OMIM 162200), Noonan syndrome (NS, OMIM 163950), 
LEOPARD syndrome (LS, OMIM 151100), cardio-facio-cutaneous syndrome (CFC, 
OMIM 115150), and Costello syndrome (CS, OMIM 218040). Predisposition to 
malignancies is a known feature of NCFC syndromes with the exception of CFC.[2] 
NF1 has a birth incidence of ~1/3000 and has been showed to be caused by 
autosomal dominant loss of function mutations of the NF1 (neurofibromin 1; 
NM_000267) gene in approximately 95% of patients fulfilling the National Institutes of 
Health (NIH) clinical diagnostic criteria.[3,4,5] NF1 is located in 17q11.2 and contains 
60 translated exons distributed over ~350 kb. Most of the NF1 mutations (90 to 95%) 
are intragenic mutations (point mutation, splice mutation, small deletion, insertion, or 
duplication). The remaining NF1 mutations (5 to 10%) are microdeletions 
encompassing the entire NF1 gene and its neighbouring genes.[6] The protein 
encoded by NF1 (neurofibromin) is a Ras-GTPase activating protein (Ras-GAP) that 
acts as a negative regulator of the Ras-MAPK cascade.[7] 
Germline dominant loss-of-function mutations in the SPRED1 (sprouty-related, 
EVH1 domain containing 1; NM_152594) gene have recently been identified in five 
unrelated families and seven additional patients fulfilling the NIH diagnostic criteria 
for NF1 although no NF1 mutation was found.[8] Remarkably, their phenotype 
referred as neurofibromatosis type 1-like syndrome (NFLS, OMIM 611431) consisted 
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of multiple café-au-lait spots, axillary freckling, and macrocephaly but without 
neurofibromas and Lisch nodules. The SPRED1 gene, located in 15q13.2, contains 
seven coding exons, and encodes the SPRED1 protein. Sprouty (SPRY1, -2, -3, and 
-4) and SPRED (SPRED1, -2, and -3) proteins are an evolutionarily conserved family 
of membrane-associated negative regulators of growth factor-induced ERK 
activation.[9,10] SPRED1 specifically inhibits MAPK signalling by suppressing Raf 
phosphorylation and activation.[11] 
In the present study, we confirmed the existence of loss-of-function mutations of 
SPRED1 and the characterization of a NCFC syndrome with a NF1 overlapping 
phenotype. We identified three nonsense mutations, one missense mutation, and 
one frameshift deletion of SPRED1 among 61 families fulfilling NIH diagnostic criteria 
for NF1 but with no identifiable NF1 mutation. We then developed a molecular 
diagnostic algorithm for individuals displaying a NF1-like phenotype tailored to routine 
clinical practice. 
 
PATIENTS, MATERIALS, AND METHODS 
Patients 
A database devoted to neurofibromatosis 1 has been established in France thanks to 
a grant from the French Clinical Research Program (coordinator: Pr. P. Wolkenstein, 
Henri Mondor Hospital, Créteil, France). The collection consists of 561 families, 
including 1697 individuals among which 1083 were NF1 patients fulfilling the NIH 
diagnostic criteria. The phenotype of each patient was described in a standardised 
way and was coupled with a comprehensive analysis of the NF1 mutational spectrum 
including intragenic microsatellites polymorphisms study, NF1 sequencing at both 
RNA and DNA levels, and real-time PCR-based gene dosage (data not shown). 
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Among the 561 NF1 index cases, a NF1 mutation was successfully identified in 512 
individuals. The 49 NF1 index cases lacking NF1 mutations were selected as a first 
panel from this NF-France database to be screened for SPRED1 mutation.  
A second panel of 12 NF1 clinically diagnosed index cases with no NF1 mutation 
was phenotypically selected from routine genetic counselling: their phenotypes lied 
within the NF1 spectrum but were distinctive, with a high prevalence of café-au-lait 
spots, axillary, and groin freckling but absence of neurofibromas and Lisch nodules. 
All blood samples drawn for nucleic acids (DNAs and RNAs) extraction were 
collected after informed consent. 
 
DNA and RNA extraction 
High-molecular-weight DNA was prepared by standard proteinase K digestion 
followed by phenol-chloroform extraction from whole-blood leukocytes. Total RNA 
was extracted from whole-blood leukocytes by using the acid-phenol guanidium 
method. The quality of the nucleic acids was determined by electrophoresis through 
agarose gels and staining with ethidium bromide (DNA and RNA) and the 18S and 
28S RNA bands were visualized under ultraviolet light (RNA). 
The somatic leukaemia DNA was extracted from bone marrow of patient II: 1 in 
Family 4 (showing 85% of blastic cells) upon diagnosis of acute leukaemia. 
 
SPRED1 mutation screening  
We performed SPRED1 mutation screening at both RNA and genomic DNA levels. 
Mutational screening of SPRED1 was carried out on RNA through the following 
procedure. After reverse transcription with Superscript II RNase H-Reverse 
Transcriptase (Invitrogen), two overlapping PCR fragments were generated by 
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Taqman PCR Core Reagent Kit (Applied Biosystems). Mutation screening was 
performed with the ABI BigDye terminator sequencing kit (Applied Biosystems) on an 
ABI Prism 3130 automatic DNA sequencer (Applied Biosystems). Sequences were 
aligned with Seqscape® analysis software (Applied Biosystems). The primer 
oligonucleotide sequences and PCR conditions are available on demand. 
Genomic DNA was amplified with primers specific for SPRED1 coding exons and 
their IVS boundaries. The primer oligonucleotide sequences and PCR conditions are 
available upon request. PCR was performed with the Taqman PCR Core Reagent Kit 
(Applied Biosystems). Mutation screening was performed using bidirectional DNA 
sequencing of purified PCR products. 
 
SPRED1 real-time PCR-based gene dosage 
In this method, quantitative values are obtained from the threshold cycle number at 
which the increase in the signal associated with exponential growth of PCR products 
begins to be detected by Applied Biosystems analysis software. The precise amount 
of genomic DNA added to each reaction mix (based on optical density) and its quality 
(i.e. lack of extensive degradation) are both difficult to assess. We therefore also 
quantified the ALB gene (encoding albumin and mapping to chromosome region 
4q11-q13) as an endogenous DNA control, and each sample was normalized on the 
basis of its ALB content. The relative SPRED1 copy number was also normalized to 
a calibrator, or 1X sample, consisting of genomic DNA from a normal subject. Final 
results, expressed as N-fold differences in the target gene copy number relative to 
the ALB gene and the calibrator, and termed "Ntarget", were determined as follows: 
Ntarget = 2(∆Ctsample - ∆Ctcalibrator), where ∆Ct values of the sample and calibrator are 
determined by subtracting the average Ct value of the target gene from the average 
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Ct value of the ALB gene. Given the target gene marker, samples with Ntarget values 
of 0.5 and 1.0 were considered deleted and normal, respectively. Primers for ALB, 
and SPRED1 gene dosage were chosen with the assistance of the computer 
program Oligo 4.0 (National Biosciences). SPRED1 exons 3, 4, and 8 were quantified 
to copy number. The primer oligonucleotide sequences and PCR conditions are 
available upon request. All PCR reactions were performed with an ABI Prism 7900 
Sequence Detection System (Applied Biosystems) and the SYBR® Green PCR Core 
Reagents kit (Applied Biosystems). Experiments were performed in triplicates for 
each data point. 
 
RESULTS 
Germline DNAs molecular analysis 
49 index cases with no identifiable NF1 mutation from the French NF1 database were 
screened for mutation in the SPRED1 gene. Two SPRED1 heterozygous nonsense 
mutations were identified at both DNA and RNA levels: one known mutation (Family 
1: c.190C>T leading to p.Arg64Stop) and one novel mutation (Family 2: c.637C>T 
leading to p.Gln213Stop) (Figure 2). 
SPRED1 mutational analysis of an additional set of 12 index cases selected from 
routine genetic counselling on the basis of their NF1-like phenotype (presence of 
café-au-lait spots and/or freckling and absence of neurofibroma and Lisch nodule), 
identified three novel heterozygous mutations: one missense mutation (Family 3: 
c.2T>C leading to p.Met1Thr), one nonsense mutation (Family 4: c.46C>T leading to 
p.Arg16Stop), and one frame-shift deletion (Family 5: c.1048_1060del leading to 
p.Gly350fs) (Figure 2). 
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In families 1, 2, and 3, the SPRED1 mutations were present in all affected 
individuals and were absent in three tested unaffected relatives (Family 1: individual 
II: 1, Family 2: I: 1, and Family 3: I: 1) (Table 1). In families 4 and 5 the propositus 
showed SPRED1 mutations. 
No SPRED1 deletion was found using real-time PCR-based gene dosage in any of 
the patients tested. 
The clinical features of SPRED1 tested individuals of families 1, 2, 3, 4, and 5 are 
displayed in Table 1. 
Molecular analysis of the somatic leukemic cells of patient II: 2 (Family 4) 
In order to test the tumour-suppressor gene hypothesis, SPRED1 molecular analysis 
was performed on the leukemic cells DNA of patient II: 2 of Family 4. No somatic 
additional SPRED1 alteration (including point mutation and loss of heterozygosity) 
was observed. 
 
DISCUSSION 
The purpose of this study was to confirm the recently identified loss-of-function 
mutations of SPRED1 in a new NF1 overlapping syndrome [8] (named NFLS) and to 
specify its phenotype and incidence. We confirmed one known mutation 
(p.Arg64Stop) described in the original paper of Brems et al.[8] and reported four 
novel mutations (p.Gln213Stop, p.Met1Thr, p.Arg16Stop, and p.Gly350fs) in five 
French families fulfilling NIH NF1 diagnostic criteria. Similar to the mutation 
p.Gln215Stop previously reported by Brems et al.[8] the nonsense mutation 
p.Gln213Stop found in Family 2 also affected exon 7 of SPRED1. The missense 
mutation c.2T>C (leading to p.Met1Thr) identified at both DNA and RNA levels (ruling 
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Table 1: Patients clinical features and SPRED1 analysis results. CAL, café-au-lait. U, unknown. M, male. F, female. -, negative. WT, Wild type for SPRED1 mutational analysis. 
Subject SPRED1 
analysis Gender 
Age 
bracket 
(years) 
weight 
(kg) 
Length 
(cm) 
Head 
Circumference CAL spots Axillary 
freckling 
Inguinal 
freckling 
Neurofibromas, 
Lisch nodules,  
Optic glioma 
Other 
(cm) (percentile) 
< 
1.5 
cm 
> 
1.5 
cm 
Family 1              
I:2 C.190C>T F [70-74] 78 147 57 50-95 5 1 unilat - - One lipoma 
II:1 WT F [40-44] U U U  - - - - -  
II:2 C.190C>T M [40-44] 92 172 58.5 50-95 3 3 - unilat - Cephalalgia; learning disability 
II:4 C.190C>T F [40-44] U 163 58 > 95 2 2 bilat - - One lipoma; Macrocephaly 
III:2 C.190C>T M [10-14] 64 169 56.5 50-95 8 3 bilat bilat - Cephalalgia 
III:3 C.190C>T M [5-9] 22 115 52 50 5 4 - unilat -  
Family 2              
I:1 WT F [60-64] U U U  - - - - -  
I:2 c.637C>T M [55-59] 80 168 57 50-95 2 5 unilat unilat -  
II:2 c.637C>T M [35-39] 76 170 54 5-50 5 4 - - -  
II:4 c.637C>T M [30-34] 78 178 U  10 4 bilat bilat -  
II:6 c.637C>T M [30-34] 68 172 56 5-50 5 4 - - -  
II:7 c.637C>T F [25-29] 55 165 55 5-50 11 10 bilat bilat -  
II:8 c.637C>T M [10-14] 31 150 52 5-50 7 7 unilat bilat - Epilepsy 
III:1 c.637C>T M [5-9] 19 U 52 5-50 5 4 unilat unilat - Learning disability 
Family 3              
I:1 WT M [40-44] 90 170 58 50-95 - - - - - Body diffuse freckling 
I:2 c.2T>C F [40-44] 67 144 53 5-50 4 5 unilat - - Cephalalgia 
II:3 c.2T>C F [10-14] 42 146 52 5-50 10 10 bilat bilat - Learning disability: dyslexia, dysgraphia, 
attention deficit; cephalalgia 
II:4 c.2T>C M [5-9] 23 124 52 5-50 4 3 - - - Diffuse freckling on face and back; weak 
speech and language delay 
Family 4              
I:1 c.46C>T M [35-39] 65 176 55 5-50 - 2 - - -  
II:2 c.46C>T M [0-4] 14 106 53 50-95 13 - - - - Monoblastic acute leukemia; 
Learning disability 
Family 5              
III:7 c.1048_1060del F [35-39] 59 165 U U 15 19 Diffuse freckling -  
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out a putative RNA decay) at the initiation codon in exon 2 abolished initiation of 
translation at the normal start site. Although the first new potential AUG codon 
downstream of the mutation at the position corresponding to methionine 21 could 
conceivably be used as an in-frame initiation codon, the loss of 20 amino acids from 
the Ena/vasodilator-stimulated phosphoprotein (VASP) homology (EVH-1) N-terminal 
functional domain of SPRED1 would probably result in a non-functional protein. It is 
notable that most of the reported mutations of SPRED1 affect the EVH-1 domain.[8] 
Nonetheless; the precise consequences of the p.Met1Thr mutation at the protein 
level remain to be determined by experimental means. The frame-shift deletion 
p.Gly350fs affected the C-terminus SPROUTY-like (SPR) domain of SPRED1, like 
p.Ser383fs previously reported.[8] These five mutations may result in a loss of 
function of SPRED1, known to inhibit the Ras-MAPK cascade, consistent with the 
concept that NCFC syndromes are caused by aberrant activation of this pathway. 
The mechanism of inheritance in the two large families 1 and 2 (with five and seven 
affected and mutated individuals respectively) was compatible with an autosomal 
dominant pattern with complete penetrance. The clinical features of patients with 
SPRED1 defects in our study (Table 1) were quite similar to the ones described by 
Brems et al.[8] The phenotype lied within the NF1 spectrum but was distinctive, with 
a high prevalence of café-au-lait spots and axillary and groin freckling and an 
absence of neurofibromas and Lisch nodules. Remarkably, some previously 
additional reported features were also found in the reported patients: learning 
disability was observed in four of the five reported families (Families 1, 2, 3, and 4) 
and lipomas in one family (Family 2). However, macrocephaly was found in only one 
individual and Noonan-like dysmorphy was not observed in any of the five families 
(Table 1) contrary to the original description of Brems et al.[8] Based on these 
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observations, the designation “Neurofibromatosis 1-like phenotype” does not seem 
appropriate because of the absence of neurofibroma. We therefore propose to 
rename the condition caused by heterozygous SPRED1 mutations as “Legius 
syndrome”. The café-au-lait spots and freckling found in SPRED1 mutated patients in 
our study were similar to those found in NF1 patients with NF1 mutations. Therefore 
NF1 and SPRED1 mutated patients could not be distinguished on the dermatologic 
features (aspect and number) of their café-au-lait spots and freckling. Moreover, 
learning disability seems to be a quite constant feature of this new syndrome. It is 
noteworthy that the behavioral deficits of Spred1-/- and Spred1+/- mice mimic the 
neurocognitive impairments in Nf1+/- mice with a remarkably similar synaptic 
phenotype. [12] 
Among the 561 NF1 index cases of the first panel (fulfilling the NIH diagnostic 
criteria for NF1), 91% (512/561) showed a NF1 mutation, 0.5% (2/561) showed a 
SPRED1 mutation, and 8.5% (47/561) did not show mutation in neither SPRED1 nor 
NF1. These data confirmed that SPRED1 mutations are rare events that are likely to 
be underestimated because of their mild associated-phenotype that may cause less 
medical consultations compared to NF1 cases with neurofibromas. The NF1-like 
phenotype (here defined as café-au-lait spots and/or freckling with no neurofibroma 
and no Lisch nodule) had a poor prevalence among all NF1 cases: among the 561 
NF1 index cases, 8% (43/561) displayed a NF1-like phenotype among which 79% 
(34/43) showed a NF1 mutation, and 5% (2/43) showed a SPRED1 mutation. Among 
the 49/561 (9%) NF1 index cases with no identifiable NF1 mutation, 9/49 (18%) index 
cases showed an NF1 like phenotype: 6 were isolated NF1 cases (only one NF1 
individual recruited per family) and 3 were families with at least two recruited NF1 
individuals. Among these three families, only two showed at least one postpubertal 
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patient (neurofibromas usually develop in the late teens or early twenties). 
Interestingly, these two families were exactly those showing a SPRED1 mutation 
(Family 1 and Family 2). In light of these new observations, we adapted our 
molecular diagnostic strategy to routine clinical practice: post pubertal patients with a 
family history of café-au-lait spots and/ or freckling with neither neurofibromas nor 
Lisch nodule are now screened for mutation in SPRED1 before performing NF1 
screening. Families 3, 4, and 5 satisfied these conditions. 
It is noteworthy that patient II: 2 in Family 4 developed a monoblastic acute 
leukaemia, suggesting a possible implication of SPRED1 germline mutation. 
SPRED1 is highly expressed in hematopoietic cells and negatively regulates 
haematopoiesis by suppressing SCF and IL-3 induced ERK activation.[13] Although 
rare, inherited predispositions to myeloid leukaemia have uncovered a critical role of 
hyperactive Ras signalling in normal myeloid growth and leukaemogenesis.[14-16] 
Moreover, individuals with NS, LEOPARD syndrome, and NF1 have a higher risk of 
haematological malignancies, including AML and the rare disorder juvenile 
myelomonocytic leukaemia (JMML).[2,17] With regards to these observations, 
SPRED1 seemed to be a good candidate gene for leukaemia predisposition. 
However, molecular analysis of the tumour DNA did not show additional somatic 
SPRED1 alteration (including point mutation and loss of heterozygosity), in 
contradiction to the Knudson two-hits model for tumour-suppressor genes. 
Considering our observation and the data implicating hyperactive Ras in the 
pathogenesis of JMML, as well as the role of SPRED1 in modulating signals from 
hematopoietic growth factor receptors to Ras, it would be of interest to screen 
SPRED1 for mutation in the ~20% of JMML cases showing no mutations in either 
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KRAS, NRAS, PTPN11, or NF1 [2,18] so as to confirm its putative implication in 
leukaemogenesis.  
In conclusion, SPRED1 mutations were present in 0.5% of all NF1 cases and in 
5% of NF1 patients displaying a NF1-like phenotype. SPRED1 mutated patients did 
not display specific dermatologic features not present in NF1 patients, except for the 
absence of neurofibromas that seem to be a specific clinical feature of NF1. NIH 
diagnostic criteria for NF1 must now take into account these new data to actualize 
guidelines and to establish a specific genetic counselling. Further studies will be 
necessary to characterize the frequency of SPRED1 mutations, the exact phenotypic 
spectrum (including learning disability), and the putative complications (in particular 
haematological malignancies) of this Legius syndrome caused by a new mechanism 
through which Ras-MAPK signalling is deregulated. These findings also urge to test 
families with NF1-like phenotype with no NF1 and SPRED1 mutations for additional 
genes involved in the Ras-MAPK pathway. 
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LEGENDS TO FIGURES 
Figure 1: A schematic of Ras signaling. Germline mutations in key components of 
the Ras-mitogen activated protein kinase (MAPK) signalling pathway cause neuro-
cardio-facial-cutaneous (NCFC) syndromes. 
Figure 2. Pedigrees of families 1, 2, 3, 4, and 5. Squares and circles indicate males 
and females, respectively. Open symbols indicate unaffected individuals, filled 
symbols indicate affected individuals, arrows indicate propositus, and symbols with a 
slash indicate deceased family members. 
 


